Relevant Articles About Prostate Cancer Research and Clinical Trials
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy
KEY TAKEAWAYS The SunRISe-4 phase 2 trial aimed to assess the efficacy and safety of neoadjuvant TAR-200 plus cetrelimab vs cetrelimab alone in patients with MIBC. The primary endpoint was to determine pCR, and the secondary endpoints were pOR rate & safety....
KEY TAKEAWAYS The DEDICATION-1 phase 3 trial aimed to investigate if reduced-dose pembrolizumab is as effective as standard dosing in stage IV NSCLC. Researchers noticed a 3.2% difference in one-year survival, meeting the criteria to continue the study. Immune...
KEY TAKEAWAYS The KEYNOTE-522 phase 3 trial aimed to investigate the OS benefit of adding pembrolizumab to chemotherapy in patients with high-risk early-stage TNBC. The primary endpoints were pCR & EFS and the secondary endpoint was OS. Researchers observed a...
The EMBARK phase 3 trial aimed to examine nursing implications of efficacy, safety, and PROs for enzalutamide treatments. The primary endpoint was MFS. …
The PROREPAIR-B, PROSENZA, PROSTAC, and PROSABI observational trial aimed to investigate the impact of HRR gene mutations beyond BRCA2 in patients with mCRPC. …
Background Major histocompatibility complex class I (MHC-I) loss is frequent in non-small cell lung cancer (NSCLC) rendering tumor cells resistant to T cell lysis. NK cells kill MHC-I-deficient tumor cells, and although previous work indicated their …
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
Background Adoptive cell transfer (ACT) shows promise as an immunotherapy for melanoma and other cancers. However, there are several challenges associated with ACT such as the logistical complexity and inconsistency when using patient-derived antigen-presenting cells for …
Background Immune checkpoint inhibitors (ICIs) are standard therapy for advanced hepatocellular carcinoma (HCC). However, the efficacy of combining nivolumab and ipilimumab in Anti-PD(L)-1 Naïve and Experienced HCC patients remains unclear. Methods We retrospectively reviewed 23 patients with advanced …